Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
Learn more about:
Related Clinical Trial
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
Reduction of Demoralization After Treatment of TD With Valbenazine
Efficacy Study of Panax Ginseng to Boost Antipsychotics Effects in Schizophrenia
The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine
Dysport for the Treatment of OMD
Validation of the Implantation of a New Electrode for the Treatment of Dystonia
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia
D-Serine Treatment For Tardive Dyskinesia
Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia
Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia
Levetiracetam Treatment of Tardive Dyskinesia
The Assessment of Movement Disorders Utilizing Live Two-Way Video
Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder
Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia
Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia
Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
Extract of Ginkgo Biloba and Tardive Dyskinesia
Aim to Reduce Movements in Tardive Dyskinesia
Reducing Involuntary Movements in Tardive Dyskinesia
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia
Pyridoxal Kinase Activity in Tardive Dyskinesia
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
Piracetam for Treatment Tardive Dyskinesia
Treatment of Tardive Dyskinesia With Galantamine
Tardive Dyskinesia and Cognitive Function
Safety and Efficacy of Pyridoxal 5′ -Phosphate in the Treatment of Tardive Dyskinesia
Addressing Involuntary Movements in Tardive Dyskinesia
Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia